within Pharmacolibrary.Drugs.ATC.D;

model D05AX06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.00015999999999999999,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0029,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006,
    Tlag           = 600,            
    Vdp             = 0.0021000000000000003,
    k12             = 17.5,
    k21             = 17.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D05AX06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor used primarily in the treatment of severe chronic obstructive pulmonary disease (COPD) to reduce the risk of exacerbations. It is an orally administered, anti-inflammatory agent approved in multiple jurisdictions including the US and EU for maintenance treatment of COPD.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects after oral administration of 500 micrograms roflumilast once daily.</p><h4>References</h4><ol><li><p>Han, M, et al., &amp; Li, JT (2023). A Single-center, Open-label, Parallel Control Study Comparing the Pharmacokinetics and Safety of a Single Oral Dose of Roflumilast and Its Active Metabolite Roflumilast N-oxide in Healthy Chinese and Caucasian Volunteers. <i>Clinical pharmacology in drug development</i> 12(3) 314–323. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1209&quot;>10.1002/cpdd.1209</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36484261/&quot;>https://pubmed.ncbi.nlm.nih.gov/36484261</a></p></li><li><p>Li, Q, et al., &amp; Ding, L (2017). Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses. <i>European journal of drug metabolism and pharmacokinetics</i> 42(3) 371–381. DOI:<a href=&quot;https://doi.org/10.1007/s13318-016-0343-4&quot;>10.1007/s13318-016-0343-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27306372/&quot;>https://pubmed.ncbi.nlm.nih.gov/27306372</a></p></li><li><p>Mansilla-Polo, M, et al., &amp; Morgado-Carrasco, D (2024). [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review. <i>Actas dermo-sifiliograficas</i> 115(3) T265–T279. DOI:<a href=&quot;https://doi.org/10.1016/j.ad.2024.01.009&quot;>10.1016/j.ad.2024.01.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38224734/&quot;>https://pubmed.ncbi.nlm.nih.gov/38224734</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D05AX06;
